Publications by authors named "I Candal Casado"

Objective: We estimated the influenza vaccination effectiveness (IVE) in preventing medical consultations and hospitalizations due to influenza during the 2023/24 season.

Methods: Two test-negative case-control studies analyzed patients who consulted primary healthcare or were hospitalized for respiratory symptoms and were tested for influenza by PCR in the 2023/24 season in Navarre, Spain. Influenza vaccination status in the current and previous seasons was compared between confirmed influenza cases and test-negative controls.

View Article and Find Full Text PDF

Importance: In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) to inform vaccination campaigns.

Objective: To estimate the effectiveness of COVID-19 vaccines administered in autumn and winter 2022 to 2023 against symptomatic SARS-CoV-2 infection (with all circulating viruses and XBB lineage in particular) among people aged 60 years or older in Europe, and to compare different CVE approaches across the exposed and reference groups used.

Design, Setting, And Participants: This case-control study obtained data from VEBIS (Vaccine Effectiveness, Burden and Impact Studies), a multicenter study that collects COVID-19 and influenza data from 11 European sites: Croatia; France; Germany; Hungary; Ireland; Portugal; the Netherlands; Romania; Spain, national; Spain, Navarre region; and Sweden.

View Article and Find Full Text PDF

Although the omicron variant of SARS-CoV-2 circulated intensely during the 2021-2022 season, many patients with severe acute respiratory disease tested negative for COVID-19. The aim of this study was to assess the presence of different respiratory viruses in deceased persons. The proportion of deceased persons with respiratory viral infections in the 2021-2022 season in Navarre, Spain, was estimated considering all deaths caused by confirmed COVID-19 according to the epidemiological surveillance and the results of multiplex PCR tests for respiratory viruses performed in a sample of deceased persons with a cause of death other than COVID-19.

View Article and Find Full Text PDF
Article Synopsis
  • Respiratory syncytial virus (RSV) is a common cause of hospitalization in newborns, but the risk decreases with age, prompting the use of nirsevimab for prevention in infants during their first RSV season.
  • A study conducted in Navarre, Spain, showed that nirsevimab significantly reduced RSV hospitalizations, with a 88.7% effectiveness rate in infants who received the immunization at birth compared to those who did not.
  • Immunizing infants born between October and December 2023 was found to prevent one hospitalization for every 15.3 infants immunized, suggesting that a strategy for immunization during RSV seasons could greatly reduce pediatric hospital admissions.
View Article and Find Full Text PDF

BackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants.AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.

View Article and Find Full Text PDF